|
Palonosetron
resources
|
|
|
|
|
|
DRUG INFO
Palonosetron
Drug Name:
Palonosetron
Indication: For the treatment of aausea and vomiting associated with cancer chemotherapy
Pharmacology: Palonosetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Palonosetron is a highly specific and selective serotonin 5-HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors.
Mechanism Of Action: Palonosetron is a selective serotonin 5-HT3 receptor antagonist. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and that the released serotonin then activates 5-HT3 receptors located on vagal efferents to initiate the vomiting reflex. Therefore Palonosetron works by blocking the reception of serotonin at these 5-HT3 receptors.
Drug Category: Antiemetics; ATC:A04AA
Brand Names/Synonyms: Aloxi; Onicit; Palonosetron; Raloxifene
Dosage Forms: Not Available
Absorption: Not Available
Interactions:
DrugBank: Interactions for Palonosetron
Interactions for Palonosetron:
Palonosetron is eliminated from the body through both renal excretion and metabolic pathways.
Therefore, the potential for clinically significant drug interactions with palonosetron appears to be low.
Chemical IUPAC Name: Not Available
Chemical Formula: C19H24N2O
Half Life: Approximately 40 hours
Drug Type: Approved Drug
# Accession No: APRD00351
CAS Registry Number: 119904-90-4
|
|
|
|
|
|
Palonosetron News
(When available)
Public company news 15 Jan 2006
Pioneer Press, MGI Pharma (Nasdaq: MOGN): Said 2005 sales of its Aloxi drug — an injection to treat chemotherapy-related nausea — totaled $248 million, below MGI's ...
MGI PHARMA Provides Corporate Update; 2005 Aloxi(R) Injection ... Jan 10, 2006
Genetic Engineering News, ...-- Commercial products: Total sales of Aloxi(R) injection in 2005 increased 56% over 2004 sales of $159 million, primarily due to increased share in the ...
NWA gets extension to file reorganization plan Jan 11, 2006
Pioneer Press, Bloomington-based MGI Pharma said Tuesday that sales of its Aloxi drug missed company guidance and predicted 2006 sales beneath Wall Street views. ...
MGI Pharma Still A 'Solid Company' Despite Mixed Guidance Jan 11, 2006
Forbes MGI Pharma (nasdaq: MOGN - news - people ) to $24 from $30 after the company pre-announced slightly lower-than-expected fourth-quarter sales of Aloxi, its post ...
UPDATE 1-MGI Pharma 2006 revenue outlook below expectations Jan 10, 2006
Reuters Unaudited figures showed that sales of Aloxi, the company's treatment for chemotherapy-induced nausea and vomiting, rose 56 percent in 2005 to $248 million ...
MGI Pharma provides '06 sales guidance Jan 10, 2006
Twin Cities Business Journal, Sales of the company's Aloxi injection, a nausea drug, increased 56 percent to $248 million in 2005, including $67 million in the fourth quarter. ...
MGI Pharma "buy," target price reduced Jan 12, 2006
New Ratings In a research note published yesterday, the analyst mentions that the company has recently pre-announced its sales results for Aloxi and Giladel below the ...
MGI Pharma "neutral" Dec 27, 2005
New Ratings In a research note published this morning, the analysts mention that although the company witnessed robust Aloxi sequential sales growth of 43% in November ...
MGI PHARMA to Present at the JPMorgan Healthcare Conference Dec 21, 2005
Genetic Engineering News, MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ...
|
|
|
